WO1999053959A3 - Use of viral vectors for treatment of the injured peripheral and central nervous system - Google Patents

Use of viral vectors for treatment of the injured peripheral and central nervous system Download PDF

Info

Publication number
WO1999053959A3
WO1999053959A3 PCT/EP1999/002100 EP9902100W WO9953959A3 WO 1999053959 A3 WO1999053959 A3 WO 1999053959A3 EP 9902100 W EP9902100 W EP 9902100W WO 9953959 A3 WO9953959 A3 WO 9953959A3
Authority
WO
WIPO (PCT)
Prior art keywords
vectors
adeno
viral vectors
treatment
nervous system
Prior art date
Application number
PCT/EP1999/002100
Other languages
French (fr)
Other versions
WO1999053959A2 (en
Inventor
Patrick Norval Anderson
Yi Zhang
Paul Alexander Dijkhuizen
Joost Verhaagen
Wilhelmus Theodorus Jo Hermens
Original Assignee
Koninkl Nl Akademie Van Wetens
Patrick Norval Anderson
Yi Zhang
Paul Alexander Dijkhuizen
Joost Verhaagen
Wilhelmus Theodorus Jo Hermens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98202249A external-priority patent/EP0968724A1/en
Application filed by Koninkl Nl Akademie Van Wetens, Patrick Norval Anderson, Yi Zhang, Paul Alexander Dijkhuizen, Joost Verhaagen, Wilhelmus Theodorus Jo Hermens filed Critical Koninkl Nl Akademie Van Wetens
Priority to AU34181/99A priority Critical patent/AU3418199A/en
Publication of WO1999053959A2 publication Critical patent/WO1999053959A2/en
Publication of WO1999053959A3 publication Critical patent/WO1999053959A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the use of a viral vector other than wild type adenoviral vectors containing the gene for a nerve growth influencing molecule, for preparation of a therapeutical composition for the treatment of injuries in the peripheral or central nervous system, wherein the nerve growth influencing molecule is selected from the group consisting of neurotrophic factors, cell adhesion molecules, growth associated molecules and their receptors. The viral vector is selected from adeno-associated viral vectors (AAV) and adenoviral vectors, which adeno-associated viral vectors are preferably human adeno-associated vector-2 (AAV-2) and which adenoviral vectors are selected from the group consisting of first, second, third or further generation adenoviral vectors. The invention further relates to a method for concentrating adeno-associated viral vectors, comprising the step of banding the vectors in Iodixanol. The invention also relates to a method for transducing post-mortem human neurons in culture.
PCT/EP1999/002100 1998-04-20 1999-03-25 Use of viral vectors for treatment of the injured peripheral and central nervous system WO1999053959A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU34181/99A AU3418199A (en) 1998-04-20 1999-03-25 Use of viral vectors for treatment of the injured peripheral and central nervoussystem

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP98201254 1998-04-20
EP98201254.4 1998-04-20
EP98202249A EP0968724A1 (en) 1998-07-03 1998-07-03 Use of viral vectors for treatment of the injured peripheral and central nervous system
EP98202249.3 1998-07-03

Publications (2)

Publication Number Publication Date
WO1999053959A2 WO1999053959A2 (en) 1999-10-28
WO1999053959A3 true WO1999053959A3 (en) 2000-01-27

Family

ID=26150246

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/002100 WO1999053959A2 (en) 1998-04-20 1999-03-25 Use of viral vectors for treatment of the injured peripheral and central nervous system

Country Status (2)

Country Link
AU (1) AU3418199A (en)
WO (1) WO1999053959A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2547179A (en) * 2015-10-26 2017-08-16 Quethera Ltd Genetic construct

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025795A1 (en) * 1994-03-18 1995-09-28 Genentech, Inc. HUMAN trk RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025795A1 (en) * 1994-03-18 1995-09-28 Genentech, Inc. HUMAN trk RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DIJKHUIZEN ET AL: "ADENOVIRAL VECTOR - DIRECTED EXPRESSION OF NEUROTROPHIN - 3 IN RAT DORSAL ROOT GANGLION EXPLANTS RESULTS IN A ROBUST NEURITE OUTGROWTH RESPONSE", JOURNAL OF NEUROBIOLOGY, vol. 33, 1997, pages 172 - 84, XP002088573 *
DIJKHUIZEN ET AL: "ADENOVIRAL VECTOR-MEDIATED GENE DELIVERY TO INJURED RAT PERIPHERAL NERVE", JOURNAL OF NEUROTRAMA, vol. 15, 1906 - June 1998 (1998-06-01), pages 387 - 397, XP002088574 *
GIGER R J ET AL: "Adenovirus -mediated gene transfer in neurons: construction and characterization of a vector for heterologous expression of the axonal cell adhesion molecule axonin -1.", JOURNAL OF NEUROSCIENCE METHODS, (1997 JAN) 71 (1) 99-111. JOURNAL CODE: K9V. ISSN: 0165-0270., NETHERLANDS, XP002088575 *
HAASE G ET AL: "GENE THERAPY OF MURINE MOTOR NEURON DISEASE USING ADENOVIRAL VECTORS FOR NEUROTROPHIC FACTORS", NATURE MEDICINE, vol. 3, no. 4, April 1997 (1997-04-01), pages 429 - 436, XP002050329 *
HERMENS ET AL: "ADENOVIRAL VECTOR - MEDIATED GENE EXPRESSION IN THE NERVOUS SYSTEM OF IMMUNOCOMPETENT WISTAR AND T CELL - DEFICIENT NUDE RATS: PREFERENTIAL SURVIVAL OF TRANSDUCED ASTROGLIAL CELLS IN NUDE RATS", HUMAN GENE THERAPY, vol. 8, 1997, pages 1049 - 1063, XP002088578 *
HERMENS W T J M C ET AL: "B-50- GAP - 43 gene delivery with an adeno -associated viral vector in non-neuronal cells results in a neuron-like morphology.", THIRD MEETING OF THE EUROPEAN WORKING GROUP OF HUMAN GENE TRANSFER AND THERAPY, BARCELONA, SPAIN, NOVEMBER 17-20, 1995. GENE THERAPY 2 (SUPPL. 1). 1995. S17. ISSN: 0969-7128, XP002088581 *
HOLTMAAT A J ET AL: "Adenoviral vector -mediated expression of B-50/ GAP - 43 induces alterations in the membrane organization of olfactory axon terminals in vivo.", JOURNAL OF NEUROSCIENCE, (1997 SEP 1) 17 (17) 6575-86. JOURNAL CODE: JDF. ISSN: 0270-6474., UNITED STATES, XP002088577 *
KLEIN R L ET AL: "Recombinant adeno -associated virus ( AAV ) vectors for brain-derived neurotrophic factor (BDNF) and growth-associated protein ( GAP - 43 ) gene delivery.", 26TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, WASHINGTON, D.C., USA, NOVEMBER 16-21, 1996. SOCIETY FOR NEUROSCIENCE ABSTRACTS 22 (1-3). 1996. 316. ISSN: 0190-5295, XP002088580 *
VERHAAGEN J ET AL: "Use of viral vectors to promote neuroregeneration.", CLINICAL NEUROSCIENCE, (1995-96) 3 (5) 275-83. REF: 59 JOURNAL CODE: B9U. ISSN: 1065-6766., UNITED STATES, XP002088576 *
WANG S ET AL: "NGF gene expression in dividing and non-dividing cells from AAV -derived constructs.", NEUROCHEMICAL RESEARCH, (1998 MAY) 23 (5) 779-86. JOURNAL CODE: NX9. ISSN: 0364-3190., UNITED STATES, XP002088579 *

Also Published As

Publication number Publication date
WO1999053959A2 (en) 1999-10-28
AU3418199A (en) 1999-11-08

Similar Documents

Publication Publication Date Title
AU1539595A (en) Process for preparing recombinant adeno-associated viruses (AAVs), and uses
CA2187626A1 (en) Aav-mediated delivery of dna to cells of the nervous system
DE69739860D1 (en) Recombinant AAV for the manufacture of a medicament for gene therapy of muscle cells
Kanazawa et al. Nucleotide sequence of the genes coding for α, β and γ subunits of the proton-translocating ATPase of Escherichia coli
Zheng et al. Lentiviral Vectors and Adeno‐Associated Virus Vectors: Useful Tools for Gene Transfer in Pain Research
JP2021534809A (en) Redirection of AAV capsid orientation
DE59913833D1 (en) STRUCTURAL PROTEIN OF AAV, ITS MANUFACTURE AND USE
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
WO1998039463A3 (en) Lentivirus based vector and vector system
CA2192215A1 (en) Recombinant aav genome encoding immunodeficiency virus protein
EP1707631A3 (en) An improved method for the production and purification of adenoviral vectors
CA2232789A1 (en) Method for treating alzheimer's disease using glial cell line-derived neurotrophic factor (gdnf) protein product
WO1998055606A3 (en) Lactoferrin receptor genes of moraxella
CA2203888A1 (en) Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor
ZA952433B (en) Recombinant viruses their preparation and their use in gene therapy
Devon et al. Olfactory ensheathing cells do not requirel-ascorbic acid in vitro to assemble a basal lamina or to myelinate dorsal root ganglion neurites
Jouet et al. Exon 2 of the gene for neural cell adhesion molecule Ll is alternatively spliced in B cells
WO2002088347A2 (en) Aav helper plasmids for helper virus-free packaging and pseudo typification of aav vectors
WO2023169115A9 (en) Aav vector having high affinity with nervous system, and application thereof
CA2342770A1 (en) Ly6h gene
WO1999053959A3 (en) Use of viral vectors for treatment of the injured peripheral and central nervous system
CA2267197A1 (en) Isolation and use of motoneuronotrophic factors
DiStefano et al. Regulation of Schwann cell surface and truncated nerve growth factor receptors in vitro by axonal components
EP1905831A3 (en) Lactoferrin receptor genes of moraxella
PT990000E (en) CONJUNCTIVE TISSUE GROWTH FACTOR 3

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase